Three recent publications have demonstrated an unacceptable therapeutic index due to cardiovascular toxicity of selective cyclooxygenase-2 inhibitors when used for cancer preventive or anti-inflammatory indications (Bresalier et al, 2005; Nussmeier et al, 2005; Solomon et al, 2005). The gene discussed is PTGS2; the disease is cancer.